Home › Funds › DAVENPORT & Co LLC › ABT

DAVENPORT & Co LLC position in ABT

ABBOTT LABORATORIES · Health Care

DAVENPORT & Co LLC reported holding 1,812,141 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$180.1M, representing 1.14% of its reported portfolio and ranking #9 among its reported holdings. DAVENPORT & Co LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.81M sh
Reported value held$180.10M
Portfolio Weight1.14%
First reportedQ3 2023
Last changeReduce
Updated2026-10-14

Last updated: 2026-10-14 · Source: SEC EDGAR Form 13F-HR

How DAVENPORT & Co LLC's ABT position evolved

DAVENPORT & Co LLC first disclosed a stake in ABT in Q3 2023 at 955,567 shares (US$92.8M). The position peaked in Q3 2026 at 1,812,141 shares, worth US$180.1M. Across 13 filings, DAVENPORT & Co LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,812,141 shares valued at US$180.1M — a reduction of -14,872 shares quarter over quarter.. Notable position changes include a 92% increase in Q2 2026 (shares rose 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 955.57K $92.82M New
Q4 2023 965.53K $106.32M Add
Q1 2024 966.45K $109.78M Hold
Q2 2024 935.18K $97.32M Reduce
Q3 2024 935.58K $106.36M Hold
Q4 2024 936.76K $105.89M Hold
Q1 2025 953.36K $126.11M Add
Q2 2025 961.06K $130.39M Add
Q3 2025 949.78K $127.05M Reduce
Q4 2025 941.49K $118.05M Reduce
Q1 2026 950.06K $97.37M Add
Q2 2026 1.83M $166.73M Add
Q3 2026 1.81M $180.10M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has DAVENPORT & Co LLC held ABT?

DAVENPORT & Co LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is DAVENPORT & Co LLC's current position in ABT?

As of Q3 2026, DAVENPORT & Co LLC holds 1.81M shares of ABT (ABBOTT LABORATORIES), valued at $180.10M, representing 1.14% of its reported portfolio and ranking #9.

Has DAVENPORT & Co LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), DAVENPORT & Co LLC reduced its position in ABT. The position peaked in Q3 2026 at 1.81M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.